Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. - Wikidata - wikimedia - TriplyDB

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

http://www.wikidata.org/entity/Q34143721

about

Topical pimecrolimus for eczema Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients An Alternative Approach to Atopic Dermatitis: Part II—Summary of Cases and Discussion Nonsteroidal Topical Immunomodulators in Allergology and Dermatology Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis.Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies.Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysis Long-term safety of tacrolimus ointment in children treated for atopic dermatitis.Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches New insights into atopic dermatitis.Pimecrolimus for the treatment of inflammatory skin disease.Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.Atopic dermatitis disease control and age: A cohort study.The role of topical calcineurin inhibitors in atopic dermatitis.Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.The effect of TJ-15 plus TJ-17 on atopic dermatitis: a pilot study based on the principle of pattern identification Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.Problem-based learning: a review of current issues relevant to physiotherapy education.Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.A systematic review of the safety of topical therapies for atopic dermatitis.Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.Pimecrolimus versus topical corticosteroids in dermatology.Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004-2012.Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.Pimecrolimus cream in the management of patients with atopic eczema.Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.How are eczema 'flares' defined? A systematic review and recommendation for future studies.Treatment of atopic dermatitis with pimecrolimus - impact on quality of life.Efficacy of topical azathioprine and betamethasone versus betamethasone-only emollient cream in 2-18 years old patients with moderate-to-severe atopic dermatitis: A randomized controlled trial.Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.Study of the Atopic March: Development of Atopic Comorbidities.[Antipruritic effects of pimecrolimus and tacrolimus].

P2860

Q24243250-D5E65891-090A-40E7-A69A-708324A7B385 Q24675365-C7C3D2FC-6CF2-4E4A-B0FB-107B58A5CD54 Q24806074-9D47FAAF-9969-42AA-B0F1-104B21ADB486 Q26752832-AC97FAAE-920E-454E-A576-8C4E5C332817 Q28086973-864E420C-8213-4037-B7E3-C14A2E889D40 Q31149849-863F02C5-30ED-481E-B4E7-68018A00868A Q34497913-DA039DE2-6707-4A66-A60A-12251E106C3A Q34552586-D585A5D2-01B5-4E49-A29D-273C156D8131 Q35077866-09CA335A-CD1F-4472-93CA-BF669BEBAD15 Q35106685-8CCA2820-4786-45D7-B7A3-E90EE5F5C745 Q35137660-E3204DAB-C7B6-47A0-8F6C-B82A483CE133 Q35208400-BECB2CC6-E47A-4B71-B8DA-8D1B35431921 Q35603170-408610D5-C7BB-49EA-A261-0E2621823511 Q35678332-66869452-0777-4262-8AA4-0E6F58CFB6DF Q35688189-6CD9AF3C-1DEE-465A-908C-C8FB42841620 Q35809490-35A9C46D-75E5-4142-89D5-11D6E47F2FBD Q35828352-3C859CED-CEED-44DB-A734-96B9EBA9C72B Q35952647-ED7D133A-1C88-49F1-9D76-2813233D71DA Q36042131-9E402DB2-014B-493D-A606-D1048D0A89AD Q36079836-BF61AA23-8C30-4689-913C-E35A0160787B Q36222741-6FF8505E-00E6-4CCC-90F0-14BF30B00536 Q36305883-9E97524C-E959-408D-B917-E5E6A528B20D Q36356956-328342DD-98FA-4784-BB01-1B56FC0CA9AF Q36574341-6093CF1E-1936-49BF-8DF5-C2B4C0247799 Q36708358-74E3872B-E4F0-4E82-8940-650AAB522282 Q36861654-B58C58A2-0ED2-4BDF-86D1-C026D1B82C1D Q36892767-77EE1611-3F71-4E88-8F9E-256A5C769969 Q36895865-875B5020-0E0C-491A-9333-F9CDAD2692F9 Q37049981-62F02BB2-423A-44CF-8112-4721E9DC1BBB Q37049990-A5916408-EA9C-4DFF-8E9F-6BC936386BF2 Q37407574-2D8688CC-D4AB-4CE6-8DD8-0F6B5D4C0351 Q37731539-81D55E8E-585C-4DA2-934E-42017DCB9EF7 Q37857666-7FDF851E-5A6B-4F75-B4C9-1E57F14D17C7 Q38123240-4F16C6B2-B22B-49D6-BB3F-2D38AFF73B88 Q38165233-C96DC221-BB24-4CE7-9E91-342CFA2D6158 Q38536150-51EF5E87-E93B-451B-9C52-75C242971D1A Q38936835-09E4081B-FCD7-42A1-8D1C-D204423EC78A Q39355978-0FC54538-06A5-43F0-8656-426909F69CEE Q40713406-0F31D5AC-06DE-45E3-BAB2-A2F4E1F035FE Q44420847-86B63A46-8E3A-4C1A-8790-E83D147C81C7

P2860

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

http://www.wikidata.org/entity/Q34143721

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Long-term management of atopic ...... teroid anti-inflammatory drug.

@ast

Long-term management of atopic ...... teroid anti-inflammatory drug.

@en

Long-term management of atopic ...... teroid anti-inflammatory drug.

@nl

type

label

Long-term management of atopic ...... teroid anti-inflammatory drug.

@ast

Long-term management of atopic ...... teroid anti-inflammatory drug.

@en

Long-term management of atopic ...... teroid anti-inflammatory drug.

@nl

prefLabel

Long-term management of atopic ...... teroid anti-inflammatory drug.

@ast

Long-term management of atopic ...... teroid anti-inflammatory drug.

@en

Long-term management of atopic ...... teroid anti-inflammatory drug.

@nl

P1433

Q34143721-79CF33B3-F025-45A8-82F4-DBE9EB2EA642

P1476

Q34143721-C898B350-8D11-44C1-95D5-682C442A7903

P2093

Q34143721-084B914D-F010-4039-AEBB-42A2D64B8FBC

Q34143721-19F86126-08AC-47FD-A980-748C2AD67EB5

Q34143721-22651DF5-B77F-4585-9CD0-F954A0AF4404

Q34143721-2BAC8790-46E2-4DEC-8AAE-64AC201BDEC4

Q34143721-46BC1758-260A-4870-8FFF-7416976DF134

Q34143721-7CEA6554-751C-4264-A3D6-3F366D648D13

Q34143721-AC8D9DA5-7325-44AE-A0AD-0DCC56B1D7DB

Q34143721-D5470635-3414-41F1-A29D-1A2283B1EC94

Q34143721-E0120686-C636-4A92-9FFE-9C180FB40D12

Q34143721-F3B4A2A8-537B-416F-AB05-FBBF07FD2CBA

P304

Q34143721-39F9EEEE-44CD-4912-BAC5-6D5FFF1BA0F8

P31

Q34143721-E3ED6081-2828-4E6F-AE82-50FE205800BC

P356

Q34143721-5DEEB6F0-E4FC-409F-954E-5CF6A53FA821

P407

Q34143721-A01D0061-905A-4329-BED9-4C6EF667A8BD

P433

Q34143721-6ECFCDA4-B653-4051-AA19-4E07AC7BE08E

P478

Q34143721-D8121899-3084-4960-8DD4-E21EC30ECFDD

P50

Q34143721-264DA71D-A8C7-494B-90BC-5123E86D090D

Q34143721-78C69397-8806-4F92-896D-B350E1BC0F1E

P577

Q34143721-0B796234-B569-4D2A-B6CC-27630E913B64

P698

Q34143721-EA933E37-1B24-4E45-8101-F86F293B8218

P921

Q34143721-5BCF212F-BE50-4023-808E-F9F8DCEB8D8F

P356

MAI.2002.126500

P1433

The Journal of Allergy and Clinical Immunology

P1476

Long-term management of atopic ...... steroid anti-inflammatory drug

@en

P2093

Alexander Kapp

http://www.w3.org/2001/XMLSchema#string

Ann Bingham

http://www.w3.org/2001/XMLSchema#string

Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Ortonne

http://www.w3.org/2001/XMLSchema#string

Mark Thurston

http://www.w3.org/2001/XMLSchema#string

Nathalie Barbier

http://www.w3.org/2001/XMLSchema#string

Paul C Potter

http://www.w3.org/2001/XMLSchema#string

Regina Fölster-Holst

http://www.w3.org/2001/XMLSchema#string

Stephen Molloy

http://www.w3.org/2001/XMLSchema#string

Wayne Gulliver

http://www.w3.org/2001/XMLSchema#string

P304

277-284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1067/MAI.2002.126500

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12170269

http://www.w3.org/2001/XMLSchema#string

P921